CLINICAL TRIALS Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma? PRET Ziada Trial Results Jithin Yohannan, BA; Beatriz Munoz, MS; Harran Mkocha, BS; Charlotte A. Gaydos, PhD; Robin Bailey, MD, PhD; Thomas A. Lietman, MD; Thomas Quinn, MD; Sheila K. West, PhD Importance: The World Health Organization recom- Interventions: Cessation of MDA with azithromycin mends at least 3 annual mass drug administrations if the community had no infection in their sample at 6 (MDAs) of azithromycin in places where the prevalence months or 18 months. of follicular trachoma (FT) is greater than 10%. How- ever, stopping MDA prior to 3 rounds, if monitoring in- Main Outcome Measure: The prevalence of C tra- dicates an absence of infection with Chlamydia tracho- chomatis at 18 months. matis even if FT persists, may be more cost-effective. Results: None of the intervention communities met cri- Objective: To determine the prevalence of infection in teria to stop MDA based on the 6-month or 18-month communities randomized to 3 rounds of annual MDAs survey; all, as well as the usual care communities, were with azithromycin compared with communities random- scheduled for a third MDA round.
JAMA Ophthalmology – American Medical Association
Published: Apr 1, 2013
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera